Skip to main content
H. Lundbeck A logo

H. Lundbeck A — Investor Relations & Filings

Ticker · HLUN ISIN · DK0061804770 LEI · 5493006R4KC2OI5D3470 CO Manufacturing
Open in API
Filings indexed 947 across all filing types
Latest filing 2022-01-24 Regulatory Filings
Country DK Denmark
Listing CO HLUN

About H. Lundbeck A

https://www.lundbeck.com/global

H. Lundbeck A/S is a global biopharmaceutical company specializing in brain diseases. The company is engaged in the research, development, manufacturing, and marketing of transformative therapies for a range of psychiatric and neurological disorders. Its portfolio and pipeline focus on conditions such as depression, mood disorders, and rare childhood-onset epilepsies. Lundbeck is dedicated to advancing neuroscience to improve the quality of life for individuals affected by central nervous system disorders.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2022
Regulatory Filings Classification · 98% confidence The document is a press release from H. Lundbeck A/S dated January 24, 2022, announcing that the European Commission has granted marketing authorization for Vyepti® (eptinezumab). It details the approval, clinical trial data, expected launch, and the impact on contingent value rights (CVRs). This type of announcement, which communicates a significant corporate event (a regulatory approval) and provides key financial/operational context, is characteristic of a general corporate announcement or press release. Since it is not a full annual report (10-K), a quarterly report (IR), a specific earnings release (ER), or a dedicated management discussion (MDA), and it is not merely announcing the publication of another report (RPA), the most appropriate classification is the general Regulatory Filings category (RNS), which serves as a broad category for significant, non-standardized corporate news releases.
2022-01-24 English
Vyepti[®] (eptinezumab) approved by the EU Commission for the preventive treatment of migraine in adults
Regulatory Filings Classification · 95% confidence The document is a 'Corporate Release' from H. Lundbeck A/S announcing the EU Commission's marketing authorization for the drug Vyepti. It details the clinical trial results, the impact on the company's strategy, and specifically mentions that this approval triggers a milestone payment for Contingent Value Rights (CVRs). While it discusses financial implications (CVR payments), it is primarily a regulatory/corporate announcement regarding product approval and milestone achievement, which falls under the 'Regulatory Filings' (RNS) category as it is a general corporate announcement that does not fit into more specific categories like Earnings Release or M&A.
2022-01-24 English
Board/Management Information 2021
Board/Management Information Classification · 99% confidence The document is titled 'Corporate Release' and its main subject is the announcement that the Chief Financial Officer (CFO) is departing and the search for a successor will begin. This directly relates to changes in senior management personnel. Based on the provided definitions, the category 'Board/Management Information (Code: MANG)' covers 'Announcement of changes in the company's board of directors or senior management.' The document is a clear announcement of a senior management change.
2021-12-07 English
Lundbeck announces changes to Executive Management
Board/Management Information Classification · 100% confidence The document is a corporate announcement regarding the departure of the company's Chief Financial Officer (CFO). This falls directly under the category of changes to senior management. The document is not a report itself but an announcement of a management change, fitting the 'MANG' category.
2021-12-07 English
Regulatory Filings 2021
Regulatory Filings Classification · 97% confidence The document is titled 'Corporate Release' and announces a positive opinion from the CHMP regarding the marketing authorization for Vyepti® in the EU. It contains key financial and operational updates (drug approval status, clinical trial results, revenue figures for 2020) but is not a comprehensive annual report (10-K) or a detailed interim report (IR). It is a specific, timely announcement of a significant business event (regulatory milestone) intended for investors and the public. This fits best under the general 'Regulatory Filings' (RNS) category as a corporate announcement, although it shares characteristics with an Earnings Release (ER) or a Legal/Regulatory update. Given the nature of a 'Corporate Release' announcing a regulatory decision, RNS is the most appropriate general category for non-standard, material announcements not covered by ER, IR, or specific transaction codes. The length (9601 chars) is substantial, ruling out a simple RPA, and the content is substantive news rather than just a summary.
2021-11-12 English
Legal Proceedings Report 2021
Legal Proceedings Report Classification · 99% confidence The document is titled 'Corporate Release' and dated October 1, 2021. The content details a specific legal outcome regarding patent litigation for the drug Trintellix in the U.S. court system, including findings on patent validity and infringement against generic manufacturers. This type of announcement, which reports on significant legal proceedings and their impact on product exclusivity, fits best under the 'Legal Proceedings Report' category. It is not a full financial report (10-K or IR), an earnings release (ER), or a general regulatory filing (RNS), but a specific update on a lawsuit. Classification: Legal Proceedings Report (LTR).
2021-10-01 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.